{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:26:04Z","timestamp":1791829564401,"version":"4.3.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"merck sharp and dohme"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Perit Dial Int"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Peritonitis is a common and serious complication of peritoneal dialysis (PD). PD-associated peritonitis (PDAP) caused by Pseudomonas is usually resistant to most antibiotics, resulting in high failure rates. Ceftolozane\/tazobactam (C\/T) has been shown to be effective in treating urinary tract and intra-abdominal infections caused by beta-lactam resistant Pseudomonas and other gram-negative bacteria. Given its favourable adverse effects profile, it has a potential role in the treatment of PDAP caused by Pseudomonas species resistant to other antibiotics. Intraperitoneal administration of antibiotics admixed with PD solutions for the treatment of PDAP is associated with superior outcomes. However, there is a lack of published data on the stability of C\/T in PD solutions. Therefore, this study investigated the physical and chemical stability of C\/T in commonly used PD solutions at different temperatures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A total of 27 PD bags (3 PD bags for each type of PD solution including Dianeal\u00ae, Extraneal\u00ae, Balance\u00ae and Physioneal\u00ae PD bags) containing C\/T were prepared and stored at 25\u00b0C for 6 h, followed by 4\u00b0C for 168 h and then 37\u00b0C for 12 h. An aliquot from each PD bag was withdrawn, and the concentration of C\/T before (0 h) and after predefined time points was determined using a stability-indicating high-performance liquid chromatography assay. Samples were also assessed for pH, colour change and particulate matter immediately after preparation and on each day of analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>C\/T retained more than 97% of their initial concentration when stored at 25\u00b0C for 6 h followed by storage at 4\u00b0C for 168 h and then at 37\u00b0C for 12 h. Particle formation was not detected at any time under the tested storage conditions. The pH and colour remained essentially unchanged throughout the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These results provide a platform for clinical studies to determine the safety and therapeutic efficacy of intraperitoneal C\/T for the treatment of PDAP caused by resistant Pseudomonas species.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0896860820902590","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T08:04:25Z","timestamp":1581581065000},"page":"470-476","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Stability of ceftolozane and tazobactam in different peritoneal dialysis solutions"],"prefix":"10.1177","volume":"40","author":[{"given":"Harmanjeet","family":"Harmanjeet","sequence":"first","affiliation":[{"name":"Division of Pharmacy, School of Medicine, University of Tasmania, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Het","family":"Jani","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, School of Medicine, University of Tasmania, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Tabish R","family":"Zaidi","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, School of Medicine, University of Tasmania, Australia"},{"name":"School of Healthcare, University of Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Wanandy","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, School of Medicine, University of Tasmania, Australia"},{"name":"Department of Pharmacy, Royal Hobart Hospital, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L","family":"Castelino","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, School of Medicine, University of Tasmania, Australia"},{"name":"School of Nursing, University of Sydney, Australia"},{"name":"Peritoneal Dialysis Unit, Regional Dialysis Centre, Blacktown Hospital, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Sud","sequence":"additional","affiliation":[{"name":"Peritoneal Dialysis Unit, Regional Dialysis Centre, Blacktown Hospital, Australia"},{"name":"Department of Renal Medicine, Nepean Hospital and Nepean Clinical School, The University of Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M","family":"Peterson","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, School of Medicine, University of Tasmania, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9344-1013","authenticated-orcid":false,"given":"Rahul P","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, School of Medicine, University of Tasmania, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,2,13]]},"reference":[{"key":"bibr1-0896860820902590","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2010.00185"},{"key":"bibr2-0896860820902590","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12731"},{"key":"bibr3-0896860820902590","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2010.00131"},{"key":"bibr4-0896860820902590","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06910712"},{"key":"bibr5-0896860820902590","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001916"},{"key":"bibr6-0896860820902590","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.00748.x"},{"key":"bibr7-0896860820902590","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2016.00078"},{"key":"bibr8-0896860820902590","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-445"},{"key":"bibr9-0896860820902590","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2010.01355.x"},{"key":"bibr10-0896860820902590","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00220-16"},{"key":"bibr11-0896860820902590","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0168-2"},{"key":"bibr12-0896860820902590","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.06.024"},{"key":"bibr13-0896860820902590","unstructured":"US Food and Drug Administration. FDA Approval Label for Zerbaxa, http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206829lbl.pdf (2014, accessed 14 May 2019)."},{"key":"bibr14-0896860820902590","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2017.00115"},{"issue":"7","key":"bibr15-0896860820902590","first-page":"1159","volume":"40","author":"Tissel LA","year":"1983","journal-title":"Am J Hosp Pharm"},{"key":"bibr16-0896860820902590","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00010109"},{"key":"bibr17-0896860820902590","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy280"},{"key":"bibr18-0896860820902590","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix182"},{"key":"bibr19-0896860820902590","first-page":"CD005284","volume":"4","author":"Ballinger AE","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr20-0896860820902590","doi-asserted-by":"publisher","DOI":"10.1177\/089686080902900101"}],"container-title":["Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0896860820902590","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0896860820902590","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0896860820902590","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:32:52Z","timestamp":1777674772000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0896860820902590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,13]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1177\/0896860820902590"],"URL":"https:\/\/doi.org\/10.1177\/0896860820902590","relation":{},"ISSN":["0896-8608","1718-4304"],"issn-type":[{"value":"0896-8608","type":"print"},{"value":"1718-4304","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,13]]}}}